India is working on four Ayurvedic drugs to treat the novel coronavirus infection and the trials will begin soon: AYUSH minister.
New Delhi: India is working on four Ayurvedic drugs to treat COVID-19 and the trials will begin soon, the nation’s AYUSH minister said.
AYUSH stands for Ayurveda, yoga, Unani, Siddha and Homoeopathy, which is the nation’s traditional medicine ministry that cultures with India’s traditional form of medicine.
“The @moayush & the @CSIR_IND are working together on validating four Ayush formulations against #COVID19Pandemic and the trials will start within one week. These formulations will be tried as an add-on therapy and standard care for COVID-19 patients,” Union Minister of State for AYUSH Shripad Y Naik tweeted.
The AYUSH Ministry is working with the Council of Scientific and Industrial Research or CSIR to conduct the traditional medicine trials.
CSIR is one of the world’s largest and most diversified publicly funded scientific and industrial research organisations.
Also Read: Remdesivir To Be Made In India As Firms Get Nod From US Drug-Maker
“I am sure and quite hopeful that our traditional medicinal system will show the way to overcome this Pandemic,” Union Minister of State for AYUSH Shripad Y Naik tweeted.
So far no one has found a cure for the COVID-19 that’s wholly backed by researchers and drug-makers unanimously. Trials of different drugs are going on.
Few medical scientists have said that plasma therapy, which requires taking the antibody-rich plasma from the blood of a recovered COVID-19 patient, could help infected people combat the virus.
However, this treatment is also not 100% backed by researchers as its effectiveness remains uncertain.
Meanwhile, United States drug-maker Gilead stated signing voluntary licensing agreements with Indian pharmaceutical companies including Cipla and Jubilant Life Sciences to expand the supply of Remdesivir.
Remdesivir is an experimental drug that has shown promise in treating COVID-19.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
